2022
DOI: 10.1016/j.urolonc.2021.10.010
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
24
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(24 citation statements)
references
References 30 publications
0
24
0
Order By: Relevance
“…In addition, because F-ICG avoids unnecessary PLND, liquid biopsy has recently gained attention as a biomarker to inform clinical decision-making in PCa [ 27 ]. Recently, biomarkers have been explored for various urologic cancers, including prostate cancer [ 28 , 29 , 30 , 31 , 32 , 33 , 34 ]. Liquid biopsy is an emerging biomarker for clinical decision making in PCa [ 35 ].…”
Section: Discussionmentioning
confidence: 99%
“…In addition, because F-ICG avoids unnecessary PLND, liquid biopsy has recently gained attention as a biomarker to inform clinical decision-making in PCa [ 27 ]. Recently, biomarkers have been explored for various urologic cancers, including prostate cancer [ 28 , 29 , 30 , 31 , 32 , 33 , 34 ]. Liquid biopsy is an emerging biomarker for clinical decision making in PCa [ 35 ].…”
Section: Discussionmentioning
confidence: 99%
“…This finding was observed by a number of researchers. 7,13,15 No significant association was found between Lymphovascular and perineural invasion and Ki-67 expression. The data regarding these variables varied among authors.…”
Section: Discussionmentioning
confidence: 94%
“…Similar results were obtained in other studies as well. 7,13,14,15 Among the other parameters, overexpression of Ki-67 was associated with lymph node metastasis. This finding was observed by a number of researchers.…”
Section: Discussionmentioning
confidence: 99%
“…Along with histological staging, the application of immunohistochemistry in clinical practice is growing. Several molecular markers predict clinical outcomes of the curative treatment and can identify patients who would benefit from additional treatment (conventional or targeted therapies/immunotherapy) [ 46 , 47 ]. Therefore, optimizing patient selection through novel biomarkers and advanced imaging might improve tumor stratification and drive treatment towards personalised strategies [ 48 ].…”
Section: Discussionmentioning
confidence: 99%